Adding Streptomycin to an Intensified Regimen for Tuberculous Meningitis Improves Survival in HIV-Infected Patients

Gerardo Alvarez-Uria, Raghavakalyan Pakam, Manoranjan Midde, Pradeep Sukumar Yalla, Praveen Kumar Naik, Gerardo Alvarez-Uria, Raghavakalyan Pakam, Manoranjan Midde, Pradeep Sukumar Yalla, Praveen Kumar Naik

Abstract

In low- and middle-income countries, the mortality of HIV-associated tuberculous meningitis (TM) continues to be unacceptably high. In this observational study of 228 HIV-infected patients with TM, we compared the mortality during the first nine months of patients treated with standard antituberculosis therapy (sATT), intensified ATT (iATT), and iATT with streptomycin (iATT + STM). The iATT included levofloxacin, ethionamide, pyrazinamide, and double dosing of rifampicin and isoniazid and was given only during the hospital admission (median 7 days, interquartile range 6-9). No mortality differences were seen in patients receiving the sATT and the iATT. However, patients receiving the iATT + STM had significant lower mortality than those in the sATT group (hazard ratio [HR] 0.47, 95% confidence interval [CI] 0.24 to 0.93). After adjusting for other covariates, the mortality hazard of the iATT + STM versus the sATT remained statistically significant (adjusted HR 0.2, 95% CI 0.09 to 0.46). Other factors associated with mortality were previous ATT and low albumin concentrations. The mortality risk increased exponentially only with CD4+ lymphocyte concentrations below 100 cells/μL. In conclusion, the use of iATT resulted in a clinically important reduction in mortality compared with the standard of care only if associated with STM. The results of this study deserve further research.

Figures

Figure 1
Figure 1
Kaplan-Meier survival estimates by treatment group. iATT, intensified antituberculosis therapy; sATT, standard antituberculosis therapy; STM, streptomycin.
Figure 2
Figure 2
Adjusted hazard ratio and 95% confidence interval for mortality according to CD4+ lymphocytes using restricted cubic splines.

References

    1. Brancusi F., Farrar J., Heemskerk D. Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome. Future Microbiology. 2012;7(9):1101–1116. doi: 10.2217/fmb.12.86.
    1. Török M. E., Bang N. D., Chau T. T. H., et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS ONE. 2011;6(12) doi: 10.1371/journal.pone.0027821.e27821
    1. Ruslami R., Ganiem A. R., Dian S., et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. The Lancet Infectious Diseases. 2013;13(1):27–35. doi: 10.1016/s1473-3099(12)70264-5.
    1. Heemskerk D., Day J., Chau T. T. H., et al. Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): protocol for a randomized controlled trial. Trials. 2011;12, article 25 doi: 10.1186/1745-6215-12-25.
    1. Alvarez-Uria G., Midde M., Pakam R., Naik P. K. Initial antituberculous regimen with better drug penetration into cerebrospinal fluid reduces mortality in HIV infected patients with tuberculous meningitis: data from an HIV observational cohort study. Tuberculosis Research and Treatment. 2013;2013:7. doi: 10.1155/2013/242604.242604
    1. Te Brake L., Dian S., Ganiem A. R., et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. International Journal of Antimicrobial Agents. 2015;45(5):496–503. doi: 10.1016/j.ijantimicag.2014.12.027.
    1. Lorber J. Treatment of tuberculous meningitis. British Medical Journal. 1960;1(5182):1309–1312. doi: 10.1136/bmj.1.5182.1309.
    1. Thwaites G., Chau T. T. H., Mai N. T. H., Drobniewski F., McAdam K., Farrar J. Tuberculous meningitis. Journal of Neurology Neurosurgery and Psychiatry. 2000;68(3):289–299. doi: 10.1136/jnnp.68.3.289.
    1. Thwaites G. E., Lan N. T. N., Dung N. H., et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. The Journal of Infectious Diseases. 2005;192(1):79–88. doi: 10.1086/430616.
    1. Tho D. Q., Török M. E., Yen N. T. B., et al. Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis. Antimicrobial Agents and Chemotherapy. 2012;56(6):3074–3079. doi: 10.1128/aac.00319-12.
    1. Donald P. R. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis. 2010;90(5):279–292. doi: 10.1016/j.tube.2010.07.002.
    1. Ministry of Health and Family Welfare India. Technical and Operational Guideline for Tuberculosis Control. Ministry of Health and Family Welfare India; 2005. .
    1. Office of The Registrar General & Census Commissioner. Census of India. Office of The Registrar General & Census Commissioner, India; 2011.
    1. Alvarez-Uria G., Midde M., Pakam R., Naik P. K. Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India. Infectious Disease Reports. 2012;4(1, article e19) doi: 10.4081/idr.2012.e19.
    1. Alvarez-Uria G., Pakam R., Midde M., Naik P. K. Entry, retention, and virological suppression in an HIV cohort study in India: description of the cascade of care and implications for reducing HIV-related mortality in low- and middle-income countries. Interdisciplinary Perspectives on Infectious Diseases. 2013;2013:8. doi: 10.1155/2013/384805.384805
    1. Alvarez-Uria G., Naik P. K., Pakam R., Bachu L., Midde M. Natural history and factors associated with early and delayed mortality in HIV-infected patients treated of tuberculosis under directly observed treatment short-course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases. 2012;2012:9. doi: 10.1155/2012/502012.502012
    1. Marais S., Thwaites G., Schoeman J. F., et al. Tuberculous meningitis: a uniform case definition for use in clinical research. The Lancet Infectious Diseases. 2010;10(11):803–812. doi: 10.1016/s1473-3099(10)70138-9.
    1. Kleinbaum D. G., Klein M. Survival Analysis, a Self-Learning Text. 2nd. Springer; 2005.
    1. Vittinghoff E., Shiboski S., McCulloch D. V. G. C. E. Regression Methods in Biostatistics. Springer; 2005.
    1. Orsini N., Greenland S. A procedure to tabulate and plot results after flexible modeling of a quantitative covariate. Stata Journal. 2011;11(1):1–29.
    1. Boeree M. J., Diacon A. H., Dawson R., et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2015;191(9):1058–1065. doi: 10.1164/rccm.201407-1264oc.
    1. Santha T., Garg R., Frieden T. R., et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. International Journal of Tuberculosis and Lung Disease. 2002;6(9):780–788.
    1. Jones-López E. C., Ayakaka I., Levin J., et al. Effectiveness of the standard WHO recommended retreatment regimen (Category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Medicine. 2011;8(3) doi: 10.1371/journal.pmed.1000427.e1000427
    1. Ellard G. A., Humphries M. J., Allen B. W. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. The American Review of Respiratory Disease. 1993;148(3):650–655. doi: 10.1164/ajrccm/148.3.650.
    1. Kaojarern S., Supmonchai K., Phuapradit P., Mokkhavesa C., Krittiyanunt S. Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningitis. Clinical Pharmacology and Therapeutics. 1991;49(1):6–12. doi: 10.1038/clpt.1991.2.
    1. Jindani A., Doré C. J., Mitchison D. A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. American Journal of Respiratory and Critical Care Medicine. 2003;167(10):1348–1354. doi: 10.1164/rccm.200210-1125oc.
    1. Cecchini D., Ambrosioni J., Brezzo C., et al. Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS. 2007;21(3):373–374. doi: 10.1097/qad.0b013e328012b84d.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir